Reviewed by the SwissAtlas coordination team · Last updated:
A cancer diagnosis changes everything — and often forces fast, critical decisions. For international families, navigating treatment options across borders requires clarity, coordination, and trust.
SwissAtlas provides structured, non-medical coordination with private Swiss clinics for international patients, ensuring discretion and clarity.
SwissAtlas supports international families navigating complex medical situations with discretion and clarity. Each case is handled with strict confidentiality and a structured coordination approach. Designed for sensitive situations requiring discretion and clarity.
Switzerland is chosen when families prioritise infrastructure consistency, privacy protections, and concentrated institutional quality.
SwissAtlas coordinates the administrative and logistical layer only. We do not provide diagnosis, treatment, or medical recommendations. We facilitate confidential intake, neutral clinic matching, communication governance, and documentation support.
Cancer treatment success rates reported by Swiss institutions reflect aggregated cohort outcomes, not individual predictions. The same institution may report a 90% five-year survival for early-stage breast cancer and a 35% figure for stage IV pancreatic cancer. These numbers are not comparable and should not be used to evaluate institutional quality in isolation. What matters is the outcome data for the specific indication, stage, and treatment intent that applies to the file in question.
Cancer treatment coordination in Switzerland aligns with research frameworks maintained by Swiss Cancer Research.
Case-mix variation is the primary reason published benchmarks do not transfer directly to individual planning. A centre with a high proportion of early-stage referrals will report stronger aggregate statistics than one that specialises in complex or refractory cases — even if the second centre provides superior care for exactly that population. Families should ask for indication-matched outcome data, not headline figures.
Five-year overall survival is the most widely cited metric but the least useful for individual decision-making unless broken down by stage and treatment line. More useful metrics include: progression-free survival at 12 and 24 months for advanced disease; pathological complete response rates for neoadjuvant protocols; R0 resection rates for surgical cases; and local control rates at defined intervals for radiotherapy and radiosurgery pathways.
For families evaluating second-opinion or treatment-transfer decisions, tumour board output quality is a more meaningful signal than published statistics. A tumour board that produces a written recommendation with explicit rationale, minority opinions where they exist, and a defined decision tree for contingency scenarios demonstrates interpretive rigour that outcome tables alone cannot convey.
Swiss oncology centres have documented depth in several high-complexity areas that attract international referrals. Skull-base and central nervous system tumours benefit from co-located neurosurgery, neuro-oncology, and radiosurgery expertise at major academic-private partnerships. Head and neck oncology, particularly in re-irradiation settings, draws on proton therapy access at PSI Villigen. Haematological malignancies, including relapsed and refractory cases appropriate for CAR-T evaluation, have designated programme infrastructure at leading centres.
Precision oncology — molecular profiling, targeted therapy sequencing, and clinical trial access — is well-developed in the Swiss system. Families considering Switzerland for second-opinion purposes in complex or advanced cases should assess whether the receiving institution has established tumour board infrastructure in the relevant subspecialty, not only broad oncology credentials.
The most useful pre-visit question is not "what is your success rate?" but "for a patient with this staging, this molecular profile, and this prior treatment history, what outcome distribution has your programme reported, and what are the main variables that would move a patient toward the better or worse end of that range?" This framing produces information that can be used for planning rather than a percentage that cannot be contextualised.
Families should also ask about treatment intent clarity — curative versus life extension versus quality-of-life maintenance — because outcome metrics vary entirely by intent category. A programme with strong palliative care outcomes and honest intent framing may represent better decision quality for a specific patient than one reporting curative statistics across an indiscriminate cohort.
SwissAtlas operates exclusively as a non-medical coordination platform. We do not provide clinical services, diagnoses, or treatment recommendations. All medical decisions are made by licensed Swiss institutions.
Published survival statistics are not directly transferable to individual cases. Population-level benchmarks reflect heterogeneous cohorts with different staging distributions, treatment protocols, and follow-up durations. What they do provide is a baseline: five-year survival for localised breast cancer is approximately 90%; colon cancer stage II around 80%; lung cancer stage I around 70%; pancreatic cancer across all stages around 12%. The last figure illustrates why staging context is essential before interpreting any survival data.
More useful questions to ask institutions: what is the annual volume of cases for this specific indication; what is the tumour board composition and decision cycle; what is the average time from referral to first recommendation; and what proportion of second-opinion cases result in a change of treatment plan. These operational metrics predict pathway quality more reliably than aggregated survival statistics.
The most reliable indicator of oncology institutional quality for complex cases is not a published survival statistic — it is the structure of the decision-making process. A tumour board that meets weekly, includes all relevant specialties, reviews imaging and pathology directly rather than through summaries, and produces a written documented recommendation is a more meaningful quality signal than a five-year survival figure derived from a heterogeneous historical cohort.
Families evaluating Swiss oncology centres should ask: how frequently does the tumour board meet for this indication; who sits on it; how long does a standard case review take; and in what format is the recommendation communicated to the patient and referring physician. A centre that can answer these questions specifically is one that takes tumour board governance seriously. A centre that gives a vague answer about "multidisciplinary care" without operational specifics is a yellow flag.
Access to clinical trials is a second quality indicator that is often overlooked. Swiss oncology centres affiliated with Swiss Cancer Center Network (Lausanne, Geneva, Bern, Zurich, Basel) have active trial portfolios. For patients with rare tumours or those who have exhausted standard treatment lines, access to an early-phase trial or an expanded access programme may be the most important outcome-relevant factor — and it requires being at an institution with the trial infrastructure to offer it. SwissAtlas can confirm trial availability for a specific indication as part of the pre-referral file review.
SwissAtlas coordinates non-clinical sequencing, documentation flow, and logistics governance while licensed institutions retain medical decision authority.
Records should be assembled as chronology with unresolved questions so specialist review can proceed without avoidable interpretation gaps.
Budgets should be scenario-based because pathway scope can evolve after deeper institutional evidence review.
Confidentiality is strengthened by role-based recipient controls and approved channels defined before high-sensitivity updates begin.
Timelines are safer when logistics commitments are tied to confirmed milestones rather than assumptions made before candidacy is established.
Confidential access to private medical care in Switzerland.
SwissAtlas operates at the intersection of discretion, structure, and access. Unlike traditional intermediaries, we do not promote specific clinics or treatments. Our role is to provide a neutral, structured, and confidential coordination layer for international patients navigating complex medical situations. This approach allows families to move forward with clarity, without pressure, and without exposure.
SwissAtlas is designed for: international families seeking discretion; patients requiring fast and structured access; situations where clarity and confidentiality are essential.
No medical advice. No pressure. Only structured coordination.
For full pathway context, review Cancer Treatment Switzerland, and also see the main treatment page.
For the complete strategic framework, review medical travel in Switzerland, treatment in Switzerland for international patients, and private healthcare Switzerland.